Fintech PR
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
NetworkNewsWire Editorial Coverage
NEW YORK, Oct. 3, 2024 /PRNewswire/ — Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer’s disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (GLP-1) and phosphodiesterase 5 (PDE5) inhibitor drugs show promise in treating Alzheimer’s, with companies such as Annovis Bio Inc. (NYSE: ANVS) (profile) leading the way with treatments ready for late-stage clinical trials. Beyond Alzheimer’s, the pharmaceutical industry is experiencing a surge of innovation across various disease areas. Major players, including Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK) and GSK plc (NYSE: GSK) are at the forefront of medical innovation, tackling previously intractable diseases.
- Annovis is leading the way in the development of buntanetap, currently testing the drug in pivotal clinical trials for Alzheimer’s and Parkinson’s diseases.
- The company has secured intellectual property for innovative combination therapies involving buntanetap and other drugs, including Trulicity(R) and Viagra(R), which work together to enhance cognitive function.
- Annovis’ planned phase 3 studies may evaluate both double combinations (buntanetap with GLP-1 agonist or PDE5 inhibitor) and a triple combination of all three drugs.
Click here to view the custom infographic of the Annovis Bio editorial.
Buntanetap Targeting Alzheimer’s Disease
Annovis Bio Inc. (NYSE: ANVS) is leading efforts to develop innovative and safe treatments for neurodegenerative diseases such as Alzheimer’s. The company’s main focus is enhancing nerve cell health to improve cognition in such conditions, a target that has proved elusive for peers. The company’s flagship drug candidate, buntanetap, has completed advanced-stage clinical trials for both AD and Parkinson’s disease (PD) and has shown compelling results in both indications.
Earlier in the year, Annovis shared positive data from a phase 2/3 trial evaluating buntanetap as an oral therapy for early-stage AD. This trial, which included 353 participants, assessed both the drug’s effectiveness alongside standard care, as well as providing insight on the safety profile. The results demonstrated cognitive improvements across all doses compared to placebo, with the 30mg dose showing the greatest benefit, measured by the ADAS-Cog 11 scale. These findings aligned with prior studies (NCT04524351, NCT02925650), with buntanetap also reducing key disease biomarkers including neurofilament light (NFL), tau protein and the inflammatory biomarker glial fibrillary acidic protein (GFAP). Annovis is currently planning for a confirmatory phase 3 trial in biomarker-positive early AD patients to support an anticipated New Drug Application (NDA) submission.
Recently, Annovis expanded its approach by exploring combinations of buntanetap with drugs such as Trulicity (dulaglutide) and Viagra (sildenafil), either as individual combination therapies or a three-prong approach utilizing all for their unique strengths. The three drugs bring their own strengths to the combination table. Trulicity, a popular GLP-1 agonist, has been shown to improve brain glucose metabolism. Viagra is known to enhance cerebral blood flow. Buntanetap inhibits the production of neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP-43, and improves the flow of information, offering a potential to restore cognitive function in patients.
Next-Generation AD Opportunity
Annovis recently unveiled preclinical data demonstrating that combining buntanetap with Trulicity in an Alzheimer’s mouse model yielded synergistic benefits. While both drugs individually improved cognitive function, their combined impact surpassed that of healthy controls by 16%, reinforcing the potential of combination therapies for AD treatment.
It is theorized that the improvement as a combination is undergirded by the neurotoxic inhibiting attributes of buntanetap paired with Trulicity’s ability to penetrate the blood-brain barrier and normalize glucose metabolism. This groundbreaking research marks the first instance of a treatment restoring cognitive function beyond normal levels.
“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, regarding the study results.
A Fresh Perspective on an Old Problem
The fight against neurodegenerative disease potentially could get a boost from unexpected sources, as drugs traditionally used for diabetes and erectile dysfunction (ED) are used for AD.
GLP-1 Agonists
Originally designed to treat type 2 diabetes, these drugs (such as semaglutide and liraglutide) mimic a hormone that regulates blood sugar. While helping diabetics control glucose, researchers noticed an additional benefit: significant weight loss. This led to the approval of drugs such as Wegovy for obesity treatment that act by suppressing appetite and increasing fat burning.
The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing inflammation, improving brain’s insulin sensitivity and enhancing neuroplasticity (the brain’s ability to form new connections).
Early clinical trials are promising. Mid-stage data showed Liraglutide (Victoza), a GLP-1 drug, to significantly minimized brain shrinkage in memory, learning and language areas compared to a placebo.
PDE5 Inhibitors
These medications (such as Viagra and Cialis), known for treating ED where smooth muscle contraction is paramount, are also being explored for AD. Although commonly used for their blood pressure-lowering effects, preclinical studies suggest they can improve synaptic function (communication between brain cells) and cerebral blood flow while also enhancing cognitive abilities. Currently, four oral PDE5 inhibitors are available in the United States: sildenafil (Viagra(R), Pfizer), vardenafil (Levitra/Staxyn(R), Bayer), tadalafil (Cialis(R), Eli Lilly), and avanafil (Stendra(R), Vivus).
Real-world data also paints a hopeful picture. Notably, sildenafil (Viagra) is linked to a reduced risk of dementia in patients who take it. Cleveland Clinic-led research discovered that in Alzheimer’s patients, sildenafil reduces levels of neurotoxic tau proteins, known contributors to the disease. Additionally, neurons treated with sildenafil exhibited enhanced cell growth, improved brain function and reduced inflammation, all of which are crucial for protecting against the neural degeneration associated with Alzheimer’s.
This promising research suggests both GLP-1 agonists and PDE5 inhibitors could have a neuroprotective effect, offering a new approach to combatting AD. By targeting the disease from multiple angles, these drugs hold potential for a more holistic treatment strategy.
Growing Patent Estate
Annovis has taken a proactive step to protect its intellectual property by filing three new patents for innovative combination therapies involving buntanetap. These patents encompass combinations with Trulicity and Viagra, as well as a synergistic approach using all three drugs. The combination of these drugs provides a competitive advantage to Annovis insomuch that buntanetap has completed phase 3 studies as a standalone treatment and the others are already FDA approved. To wit, Annovis is well positioned to initiate phase 3 clinical studies.
Further, this multifaceted approach offers unprecedented potential in combating neurodegeneration, especially considering the growing prevalence of AD in the U.S. Neurodegenerative diseases are on the rise, with Alzheimer’s affecting nearly 6.7 million Americans today. Without significant medical breakthroughs, this number is projected to double to 13.8 million by 2060. With buntanetap already completing phase 3 trials and Trulicity and Viagra being FDA approved, these combination therapies are well positioned for further clinical development under the protection of Annovis’ patents.
Other Innovators
A wave of innovative treatments is emerging, offering hope for patients with previously challenging conditions. The outlook is brightening as promising therapies are being developed, paving the way for a brighter future in healthcare.
Johnson & Johnson (NYSE: JNJ), a multinational pharmaceutical, biotechnology, and medical technologies corporation, is focused on healthcare innovation that builds a world where complex diseases are prevented, treated and cured; and where treatments are smarter and less invasive; and solutions are personal. Most recently the company invested more than $2 billion in new, advanced technology manufacturing facility in North Carolina to support robust portfolio growth. The new facility will expand production of Johnson & Johnson’s innovative biologic medicines in areas including oncology, immunology, and neuroscience; construction on the state-of-the-art structure is slated to begin in the first half of 2025.
Novartis (NYSE: NVS) is an innovative medicines company with research and development at its core. The company’s R&D engine powers an industry-leading pipeline that is focused on delivering transformative medicines to fight disease, restore possibility and help people live life on their own terms. The company’s researchers work across several diseases areas to drive drug discovery and early development, while its development organization leads the advanced clinical development of those medicines. This work is powered by technology platforms that help the company innovate across its core therapeutic areas: cardiovascular, renal and metabolic, oncology, immunology and neuroscience.
Merck & Co. Inc. (NYSE: MRK) is developing an investigational GLP-1/glucagon receptor co-agonist: efinopegdutide (MK-6024). The experimental drug efinopegdutide, which is being developed as a treatment for nonalcoholic steatohepatitis (NASH) and was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for this treatment, also showed a weight-loss benefit, said CEO Robert Davis during the 45th Annual Goldman Sachs Healthcare Conference.
GSK plc (NYSE: GSK) was at this year’s Alzheimer’s Association International Conference, presenting four new abstracts contributing to early science in neurodegenerative diseases. More specifically, GSK was presenting results from the ZOSTER-122 retrospective, observational matched-cohort study in adults aged 50 years and over, which examines the potential association between Shingrix (Recombinant Zoster Vaccine or RZV) vaccination and reduced risk of dementia compared to two other vaccines.
These pharmaceutical players are working to find effective treatments for diseases that for decades have been underserved. Potential breakthroughs in the development of new drugs could mean big success for these companies and, even more important, significant benefits for the individuals suffering from these diseases.
For more information about Annovis Bio Inc. (NYSE: ANVS), please visit Annovis Bio Inc.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire is powered by IBN
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, FNM, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
FNM & NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
View original content:https://www.prnewswire.co.uk/news-releases/beyond-the-horizon-innovative-drug-combinations-offer-new-hope-for-alzheimers-and-more-302266092.html
Fintech PR
Artificial Intelligence (AI) in Trading Market to Reach USD 35 Billion by 2030, Growing at a 10% CAGR | Valuates Reports
BANGALORE, India, Jan. 3, 2025 /PRNewswire/ — AI in Trading Market is Segmented by Type (Software, Services), by Application (Automotive, IT & Telecommunication, Transportation & Logistics, Energy & Utilities, Healthcare, Retail, Manufacturing).
The Global Artificial Intelligence in Trading Market was valued at USD 18 Billion in 2023 and is anticipated to reach USD 35 Billion by 2030, witnessing a CAGR of 10% during the forecast period 2024-2030.
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-30U5674/Global_Artificial_Intelligence_in_Trading_Market
Major Factors Driving the Growth of Artificial Intelligence (AI) in Trading Market:
The Artificial Intelligence in Trading market is on a robust growth trajectory, driven by the increasing adoption of AI technologies to enhance trading performance and operational efficiency. The integration of machine learning algorithms, predictive analytics, and automated trading systems is transforming the landscape of financial trading, enabling more informed and strategic decision-making. The rising complexity and volatility of financial markets necessitate advanced AI-driven solutions that can analyze vast amounts of data, identify market trends, and execute trades with precision and speed. Additionally, the continuous advancements in AI and machine learning technologies are expanding the capabilities and applications of AI in trading, making these solutions more accessible and effective for a broader range of traders and financial institutions. The growing emphasis on data-driven trading strategies, coupled with the need for competitive advantage and risk management, propels the demand for AI-driven trading technologies. As financial markets continue to evolve and embrace digital transformation, the Artificial Intelligence in Trading market is poised to achieve significant growth, driven by innovation, investment, and the increasing reliance on technology-driven trading solutions.
Unlock Insights: View Full Report Now! https://reports.valuates.com/market-reports/QYRE-Auto-30U5674/global-artificial-intelligence-in-trading
TRENDS INFLUENCING THE GROWTH OF THE GLOBAL AI IN TRADING MARKET:
Software solutions are instrumental in driving the growth of the Artificial Intelligence in Trading market by enhancing the efficiency, accuracy, and speed of trading operations. Advanced trading software incorporates machine learning algorithms, predictive analytics, and real-time data processing capabilities, enabling traders to make informed decisions based on comprehensive market insights. These software platforms facilitate automated trading strategies, allowing for the execution of trades at optimal times without human intervention, thereby reducing latency and increasing profitability. Additionally, sophisticated risk management tools integrated into trading software help in identifying and mitigating potential risks, ensuring more stable and secure trading environments. The continuous evolution of trading software, with the integration of AI-driven features such as sentiment analysis and anomaly detection, further propels market growth by offering traders innovative tools to navigate complex financial markets. The increasing reliance on technology-driven trading solutions underscores the critical role of software in expanding the Artificial Intelligence in Trading market.
Services play a pivotal role in driving the growth of the Artificial Intelligence in Trading market by providing essential support and expertise required to implement and optimize AI-driven trading strategies. These services include consulting, system integration, data management, and ongoing technical support, which are crucial for financial institutions and traders looking to leverage AI technologies effectively. Professional services help organizations navigate the complexities of AI adoption, ensuring that AI models are accurately tailored to specific trading needs and market conditions. Additionally, managed services offer continuous monitoring and maintenance of AI systems, ensuring their optimal performance and adaptability to evolving market dynamics. Training and education services further enhance the capabilities of trading teams, equipping them with the necessary skills to utilize AI tools effectively. The comprehensive range of services provided by specialized firms enables seamless integration of AI technologies into trading operations, thereby accelerating the adoption and expansion of the Artificial Intelligence in Trading market.
Financial services are a major catalyst in the growth of the Artificial Intelligence in Trading market, as they are at the forefront of adopting AI technologies to gain a competitive edge in the financial markets. Investment banks, hedge funds, asset management firms, and proprietary trading firms increasingly utilize AI-driven trading systems to enhance their trading strategies, improve decision-making processes, and optimize portfolio management. The ability of AI to analyze vast amounts of financial data, identify market trends, and execute trades at high speeds enables financial services firms to achieve higher returns and manage risks more effectively. Additionally, the integration of AI in areas such as algorithmic trading, fraud detection, and customer service enhances operational efficiency and service quality within financial institutions. The growing recognition of AI’s potential to transform trading practices and deliver superior financial performance drives the continuous investment and expansion of AI technologies in the financial services sector, thereby propelling the growth of the Artificial Intelligence in Trading market.
The increasing demand for high-speed trading is a significant factor driving the Artificial Intelligence in Trading market. In today’s fast-paced financial markets, the ability to execute trades within milliseconds can provide a substantial competitive advantage. AI-driven trading systems are designed to process large volumes of data and execute trades at speeds that far surpass human capabilities, enabling traders to capitalize on fleeting market opportunities. The rise of high-frequency trading (HFT) strategies, which rely on rapid data analysis and automated execution, underscores the need for advanced AI technologies that can deliver the required speed and precision. The growing complexity and volatility of financial markets further amplify the demand for high-speed trading solutions, as traders seek to navigate rapid price fluctuations and capitalize on minute market movements. The continuous advancement of AI technologies to enhance trading speed and efficiency drives the expansion of the Artificial Intelligence in Trading market.
The availability and integration of vast amounts of financial data are crucial drivers of the Artificial Intelligence in Trading market. The proliferation of data sources, including market feeds, news articles, social media, and economic indicators, provides a rich foundation for AI algorithms to analyze and derive actionable insights. Effective integration of diverse data sets allows AI systems to develop more accurate predictive models and trading strategies, enhancing their ability to anticipate market movements and make informed trading decisions. Additionally, the advancement of big data technologies and data processing frameworks facilitates the seamless ingestion, storage, and analysis of large-scale financial data, enabling AI-driven trading systems to operate more efficiently and effectively. The increasing emphasis on data-driven decision-making in trading practices underscores the importance of robust data integration capabilities, thereby fueling the growth of the Artificial Intelligence in Trading market.
Effective risk management and mitigation are critical factors driving the Artificial Intelligence in Trading market. AI-driven trading systems offer advanced risk assessment and management capabilities that help traders and financial institutions identify, evaluate, and mitigate potential risks in real-time. Machine learning algorithms can analyze historical and real-time data to detect abnormal trading patterns, predict market downturns, and optimize portfolio allocations to minimize exposure to adverse market conditions. Additionally, AI technologies enable the development of sophisticated hedging strategies and automated stop-loss mechanisms, enhancing the ability to manage financial risks proactively. The ability to quickly adapt to changing market dynamics and implement risk mitigation measures is essential for maintaining financial stability and achieving sustainable trading performance. As the complexity and interconnectedness of financial markets increase, the demand for robust AI-driven risk management solutions intensifies, thereby fueling the growth of the Artificial Intelligence in Trading market.
Achieving a competitive advantage is a significant driver in the growth of the Artificial Intelligence in Trading market. Financial institutions and traders seek to leverage AI technologies to gain an edge over competitors by enhancing the speed, accuracy, and efficiency of their trading operations. AI-driven trading systems enable the development of proprietary trading strategies, optimize trade execution, and improve the ability to anticipate market movements, thereby increasing profitability and market share. The ability to process and analyze vast amounts of data in real-time allows traders to make informed decisions faster than competitors relying on traditional trading methods. Additionally, AI technologies facilitate the customization of trading strategies to align with specific investment goals and risk profiles, further differentiating traders in the competitive financial landscape. The pursuit of superior performance and the need to stay ahead in the highly competitive trading environment drive the adoption and investment in AI-driven trading solutions, thereby propelling the growth of the Artificial Intelligence in Trading market.
Claim Yours Now! https://reports.valuates.com/api/directpaytoken?rcode=QYRE-Auto-30U5674&lic=single-user
AI IN TRADING MARKET SHARE
China and the United States are two leaders in the AI industry. On the AI 100 list (2022) released by CB Insights, the number of companies in the United States ranks first, with more than 70 companies, followed by the United Kingdom, with 8 companies on the list. China and Canada both hold 5 companies on the list. According to data from the China Academy of Information and Communications Technology, the scale of China’s core artificial intelligence industry reached ¥508 Billion in 2022, a year-on-year increase of 18%.
The Artificial Intelligence in Trading market exhibits significant regional variations, influenced by factors such as financial market maturity, technological infrastructure, and regulatory environments. North America leads the market, driven by the presence of major financial hubs like New York and Silicon Valley, advanced technological infrastructure, and a high concentration of fintech startups specializing in AI-driven trading solutions.
Key Companies:
- IBM Corporation
- Trading Technologies International, Inc
- GreenKey Technologies, LLC
- Trade Ideas, LLC
- Imperative Execution Inc
- Looking Glass Investments LLC
- Aitrades
- Kavout
- Auquan
- WOA
- Techtrader
Purchase Regional Report: https://reports.valuates.com/request/regional/QYRE-Auto-30U5674/Global_Artificial_Intelligence_in_Trading_Market
SUBSCRIPTION
We have introduced a tailor-made subscription for our customers. Please leave a note in the Comment Section to know about our subscription plans.
DISCOVER MORE INSIGHTS: EXPLORE SIMILAR REPORTS!
– AI Content Generation Market was estimated to be worth USD 1108 Million in 2023 and is forecast to a readjusted size of USD 5958 Million by 2030 with a CAGR of 27.3% during the forecast period 2024-2030.
– AI Crypto Trading Bot Market was valued at USD 21.69 Million in 2022 and is anticipated to reach USD 145.27 Million by 2029, witnessing a CAGR of 37.2% during the forecast period 2023-2029.
– Industrial Artificial Intelligence Market
– Artificial Intelligence for Retail Market was estimated to be worth USD 942.3 Million in 2023 and is forecast to a readjusted size of USD 1249.7 Million by 2030 with a CAGR of 3.2% during the forecast period 2024-2030.
– The global AI In Telecommunication market was valued at USD 1723 Million in 2023 and is anticipated to reach USD 19170 Million by 2030, witnessing a CAGR of 40.6% during the forecast period 2024-2030.
– Artificial Intelligence-based Security Market was estimated to be worth USD 6925 Million in 2023 and is forecast to a readjusted size of USD 20200 Million by 2030 with a CAGR of 16.4% during the forecast period 2024-2030.
– The global AI Data Center market was valued at USD 22615.04 Million in 2023 and is anticipated to reach USD 68317.57 Million by 2030, witnessing a CAGR of 17.11%during the forecast period 2024-2030.
– Artificial Intelligence (AI) in Mining Market was estimated to be worth USD 814 Million in 2023 and is forecast to a readjusted size of USD 1674 Million by 2030 with a CAGR of 11.0% during the forecast period 2024-2030.
– AI (Artificial Intelligence) Decision Making Market
– The AI Companion market was valued at USD 102 Million in 2023 and is anticipated to reach USD 632 Million by 2030, witnessing a CAGR of 98%% during the forecast period 2024-2030.
– Algorithmic Trading Software Market
DISCOVER OUR VISION: VISIT ABOUT US!
Valuates offers in-depth market insights into various industries. Our extensive report repository is constantly updated to meet your changing industry analysis needs.
Our team of market analysts can help you select the best report covering your industry. We understand your niche region-specific requirements and that’s why we offer customization of reports. With our customization in place, you can request for any particular information from a report that meets your market analysis needs.
To achieve a consistent view of the market, data is gathered from various primary and secondary sources, at each step, data triangulation methodologies are applied to reduce deviance and find a consistent view of the market. Each sample we share contains a detailed research methodology employed to generate the report. Please also reach our sales team to get the complete list of our data sources.
GET A FREE QUOTE
Valuates Reports
[email protected]
For U.S. Toll-Free Call 1-(315)-215-3225
WhatsApp: +91-9945648335
Website: https://reports.valuates.com
Blog: https://valuatestrends.blogspot.com/
Pinterest: https://in.pinterest.com/valuatesreports/
Twitter: https://twitter.com/valuatesreports
Facebook: https://www.facebook.com/valuatesreports/
YouTube: https://www.youtube.com/@valuatesreports6753
https://www.facebook.com/valuateskorean
https://www.facebook.com/valuatesspanish
https://www.facebook.com/valuatesjapanese
https://valuatesreportspanish.blogspot.com/
https://valuateskorean.blogspot.com/
https://valuatesgerman.blogspot.com/
https://valuatesreportjapanese.blogspot.com/
Logo: https://mma.prnewswire.com/media/1082232/Valuates_Reports_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/artificial-intelligence-ai-in-trading-market-to-reach-usd-35-billion-by-2030-growing-at-a-10-cagr–valuates-reports-302341827.html
Fintech PR
Bybit x Block Scholes Report: BTC Options Steady with Call-Put Parity, ETH Braces for Short-Term Volatility
DUBAI, UAE, Jan. 3, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has released its latest crypto derivatives analytics report in collaboration with Block Scholes. The report sheds light on key trends in open interest and market behavior during the significant year-end options expiration for Bitcoin (BTC) and Ethereum (ETH).
Key highlights:
Open Interest Solid Amid Year-End Options Expiration
Although open interest in BTC and ETH perpetual swaps has not returned to the early December 2024 highs, it remained stable during the critical year-end options expiration. This stability suggests that traders did not heavily rely on perpetual contracts to hedge the delta of expiring options, which contributed to the muted volatility observed during this period. Trading volumes dipped during the winter holiday season, aligning with a collapse in realized volatility, which reached its lowest levels of December.
BTC Option Curve Remains Steep During Call-Put Parity
Contrary to expectations, the expiration of December’s options did not spark a surge in volatility. Instead, realized volatility declined to the lower end of its recent range. The implied volatility term structure for BTC options remains steep, with longer-dated implied volatility hovering around 57% and 1-week at-the-money options trading approximately five points lower. Most of the expired open interest has not been reinvested, maintaining a neutral call-put balance. As a result, BTC’s options market shows limited leverage compared to its position at the beginning of December 2024, reflecting a cautious sentiment.
Huge ETH Option Expiring Doesn’t Cause Volatility
Despite the substantial expiration of ETH options in late December 2024, market dynamics remained stable. A spike in realized volatility during December failed to extend into the new year, with ETH’s spot price currently showing lower volatility compared to short-tenor implied volatility. Over the past week, the implied volatility term structure for ETH options has shifted, steepening briefly before flattening again, diverging from BTC’s consistently steep profile. This pattern suggests that ETH’s options market is bracing for potential short-term volatility in spot price movements.
Interestingly, despite the expiration, call options for ETH have gained momentum at the start of 2025, dominating the market and indicating an optimistic outlook among traders.
Access the Full Report:
Gain deeper insights and explore the potential impacts on your crypto trading strategies by downloading the full Bybit x Block Scholes Crypto Derivatives Analytics Report.
#Bybit / #TheCryptoArk / #BybitLearn / #BybitResearch / #BTC100K
About Bybit
Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 60 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: [email protected]
For updates, please follow: Bybit’s Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
Photo – https://mma.prnewswire.com/media/2590149/Bybit_x_Block_Scholes_Report_BTC_Options_Steady_Call_Put_Parity.jpg
Logo – https://mma.prnewswire.com/media/2267288/5097786/Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bybit-x-block-scholes-report-btc-options-steady-with-call-put-parity-eth-braces-for-short-term-volatility-302341877.html
ABU DHABI, UAE, Jan. 3, 2025 /PRNewswire/ — Arctech, the world’s leading solar tracking and racking solutions provider, announced that it signed a 1.5GW order of its 1P single-axis solar tracking system SkyLine II with PowerChina for a solar project in Al Ajban, UAE, marking a great start for the company in the Middle East market in 2025.
As a key initiative under “UAE Energy Strategy 2050”, which aims to provide the country with zero-emission clean energy, this 1.5GW Al Ajban Solar PV plant will become one of the largest single-site solar plants worldwide once completed.
Upon completion, this plant is projected to generate green electricity capable of fulfilling the electricity demands of approximately 160,000 households. It is expected to reduce Abu Dhabi’s annual carbon emissions by 2.4 million tons each year, thereby significantly advancing green development and facilitating energy transition in the Middle East.
Since establishing its local operations in 2017, Arctech has expanded to include a service center, an R&D center, two local offices and a manufacturing base in the Middle East. Among which, Arctech’s Jeddah Phase II manufacturing base is currently under construction and will officially enter operation in 2025. Combined with its global supply chain, this expansion will enable Arctech to achieve a local delivery capacity of 15GW.
Up to now, Arctech has established a complete full life cycle service network in the Middle East market, including technical support, supply chain delivery, after-sales service, local operation and maintenance capabilities, and brand marketing strategies. Looking ahead, Arctech is well-positioned to further contribute to UAE’s “Energy Strategy 2050” through its enhanced localization initiatives and comprehensive white-glove services.
About Arctech
Arctech (SSE-STAR:688408) is the world-leading supplier of intelligent solar trackers, fixed-tilt structures, PV cleaning robots and energy storage solutions. Empowered by over 530 patents, Arctech products have been applied in utility-scale and commercial solar PV projects since 2009. It was listed among the top 4 tracker suppliers by IHS Markit and Wood Mackenzie from 2017 to 2020. The company went public on China’s Nasdaq-style STAR market in 2020. As of June 2024, Arctech has supplied over 76 GW of tracking and racking systems to nearly 1,800 PV plants in 40 countries. For more information, please visit https://www.arctechsolar.us/. Follow us on Linkedin, Twitter, Facebook and YouTube.
Photo – https://mma.prnewswire.com/media/2589982/Groundbreadking_Ceremony_1_5GW_Al_Ajban_Solar_PV_plant.jpg
View original content:https://www.prnewswire.co.uk/news-releases/year-opening-triumph-arctech-lands-a-1-5gw-solar-project-order-in-the-uae-302341769.html
-
Fintech PR5 days agoOutsourced Accounting Service: The New Standard for Business Finance Industry
-
Fintech PR5 days agoCKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
-
Fintech PR5 days agoBybit Launchpad Onboards Xterio, Opening up Opportunities in Blockchain Gaming for Users
-
Fintech PR5 days agoIBN Technologies Sets the Benchmark in Financial Management Accounting Excellence
-
Fintech PR6 days agoIBN Technologies LLC Steps in to Support Clients After Bench Accounting’s Unexpected Closure
-
Fintech PR4 days agoDayOne Launches as an Independent Global Data Center Pioneer Following Series B Funding Closure
-
Fintech PR4 days agoGES Completes Sale to Truelink Capital
-
Fintech PR5 days agoCommercial Amino Acids Surge with 6.1% CAGR Growth: BCC Research